Ribosomal S6 kinase (RSK) modulators: a patent review
- PMID: 27410995
- DOI: 10.1080/13543776.2016.1212839
Ribosomal S6 kinase (RSK) modulators: a patent review
Abstract
Introduction: The p90 ribosomal S6 kinases (RSK) are a family of Ser/Thr protein kinases that are downstream effectors of MEK1/2-ERK1/2. Increased RSK activation is implicated in the etiology of multiple pathologies, including numerous types of cancers, cardiovascular disease, liver and lung fibrosis, and infections.
Areas covered: The review summarizes the patent and scientific literature on small molecule modulators of RSK and their potential use as therapeutics. The patents were identified using World Intellectual Property Organization and United States Patent and Trademark Office databases. The compounds described are predominantly RSK inhibitors, but a RSK activator is also described. The majority of the inhibitors are not RSK-specific.
Expert opinion: Based on the overwhelming evidence that RSK is involved in a number of diseases that have high mortalities it seems surprising that there are no RSK modulators that have pharmacokinetic properties suitable for in vivo use. MEK1/2 inhibitors are in the clinic, but the efficacy of these compounds appears to be limited by their side effects. We hypothesize that targeting the downstream effectors of MEK1/2, like RSK, are an untapped source of drug targets and that they will generate less side effects than MEK1/2 inhibitors because they regulate fewer effectors.
Keywords: BIX 02565; FMK; RSK; SL0101; p90RSK.
Similar articles
-
Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner.Cell Signal. 2015 Aug;27(8):1630-42. doi: 10.1016/j.cellsig.2015.04.004. Epub 2015 Apr 16. Cell Signal. 2015. PMID: 25889895
-
Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation.Cancer Res. 2005 Feb 1;65(3):1027-34. Cancer Res. 2005. PMID: 15705904
-
The p90 ribosomal S6 kinase (RSK) inhibitor BI-D1870 prevents gamma irradiation-induced apoptosis and mediates senescence via RSK- and p53-independent accumulation of p21WAF1/CIP1.Cell Death Dis. 2013 Oct 17;4(10):e859. doi: 10.1038/cddis.2013.386. Cell Death Dis. 2013. PMID: 24136223 Free PMC article.
-
Selective Targeting of RSK Isoforms in Cancer.Trends Cancer. 2017 Apr;3(4):302-312. doi: 10.1016/j.trecan.2017.03.004. Epub 2017 Apr 3. Trends Cancer. 2017. PMID: 28718440 Review.
-
Therapeutic targeting of p90 ribosomal S6 kinase.Front Cell Dev Biol. 2023 Dec 19;11:1297292. doi: 10.3389/fcell.2023.1297292. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 38169775 Free PMC article. Review.
Cited by
-
ERK1/2-RSK2 Signaling in Regulation of ERα-Mediated Responses.Endocrinology. 2022 Sep 1;163(9):bqac106. doi: 10.1210/endocr/bqac106. Endocrinology. 2022. PMID: 35880639 Free PMC article. Review.
-
Development of an ORF45-Derived Peptide To Inhibit the Sustained RSK Activation and Lytic Replication of Kaposi's Sarcoma-Associated Herpesvirus.J Virol. 2019 May 1;93(10):e02154-18. doi: 10.1128/JVI.02154-18. Print 2019 May 15. J Virol. 2019. PMID: 30842327 Free PMC article.
-
Role and targeting of the AGC kinase family in pulmonary fibrosis (Review).Exp Ther Med. 2024 Mar 8;27(5):190. doi: 10.3892/etm.2024.12478. eCollection 2024 May. Exp Ther Med. 2024. PMID: 38533431 Free PMC article. Review.
-
The role of the p90 ribosomal S6 kinase family in prostate cancer progression and therapy resistance.Oncogene. 2021 Jun;40(22):3775-3785. doi: 10.1038/s41388-021-01810-9. Epub 2021 May 10. Oncogene. 2021. PMID: 33972681 Free PMC article. Review.
-
ncRNAs mediated RPS6KA2 inhibits ovarian cancer proliferation via p38/MAPK signaling pathway.Front Oncol. 2023 Jan 19;13:1028301. doi: 10.3389/fonc.2023.1028301. eCollection 2023. Front Oncol. 2023. PMID: 36741009 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
